Condition Directory

Lung Cancer clinical trials

Directory of U.S. ClinicalTrials.gov public records for Lung Cancer. Browse Lung Cancer recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced November 15, 2026 Report an issue

ClinicalTrials.gov public records Last synced Nov 15, 2026, 3:06 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

5928

Shown on this page

Current sort

How Lung Cancer studies are organized in the registry

The registry splits lung cancer records between non-small cell (NSCLC) and small cell (SCLC) disease, and a large share of NSCLC studies are organized around a biomarker rather than the diagnosis alone. If a mutation or marker drives your search, query it directly — it typically appears verbatim in titles. A dedicated non-small cell lung cancer page is also available in this directory.

Terms that often appear in related listings

NSCLC small cell lung cancer EGFR ALK KRAS

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Showing 1093–1104 of 5,928 matching trials for Lung Cancer.

Live ClinicalTrials.gov results.

Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search

Conditions: NSCLC Stage IV, ALK Fusion Protein Expression
Interventions: Peptide vaccine; Biological
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Non-small Cell Lung Cancer, Lung Cancer
Interventions: valemetostat tosylate, pembrolizumab; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 11
States / cities: La Jolla, California • Los Angeles, California • Jacksonville, Florida + 7 more

Conditions: Non Small Cell Lung Cancer, Non-small Cell Lung Cancer, Small-cell Lung Cancer, Small Cell Lung Carcinoma
Interventions: ADI-PEG 20, Gemcitabine, Docetaxel; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 3
States / cities: Chicago, Illinois • St Louis, Missouri • Fairfax, Virginia

Conditions: Unresectable Pleural or Peritoneal Malignant Mesothelioma
Interventions: Tremelimumab, Placebo; Drug
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 571 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2027
U.S. locations: 21
States / cities: Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 17 more

Conditions: Bronchiolitis Obliterans Syndrome, Hematopoietic and Lymphoid Cell Neoplasm
Interventions: Home spirometry, Biospecimen Collection, Questionnaire Administration; Procedure · Other
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 8 Years and older
Enrollment: 261 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 4
States / cities: Palo Alto, California • Ann Arbor, Michigan • Houston, Texas + 1 more

Conditions: Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions: CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine, Sargramostim, Computed Tomography, Biopsy, Biospecimen Collection; Biological · Procedure
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 2
States / cities: Omaha, Nebraska • Seattle, Washington

Conditions: Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer
Interventions: Administration of ceralasertib, Administration of ceralasertib in combination with olaparib, Administation of ceralasertib in combination with durvalumab, Administration of ceralasertib monotherapy, Administration of ceralasertib and olaparib, Administration of ceralasertib and durvalumab, Administration of ceralasertib in combination with AZD5305, Administration of ceralasertib in combination with carboplatin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 358 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2026
U.S. locations: 8
States / cities: Duarte, California • Irvine, California • Los Angeles, California + 4 more

Conditions: Small Cell Lung Cancer
Interventions: NMS-03305293, Temozolomide; Drug
Lead sponsor: Nerviano Medical Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Peoria, Illinois • Boston, Massachusetts • Nashville, Tennessee

Conditions: Metastatic Cancer, Melanoma Cancer, Lung Cancer, Bladder Cancer, Renal Cancer, Head/Neck Cancers
Interventions: Stereotactic Body Radiotherapy, Ipilimumab, Nivolumab, Pembrolizumab or Atezolizumab; Radiation · Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 10
States / cities: Hartford, Connecticut • Basking Ridge, New Jersey • Middletown, New Jersey + 7 more

Conditions: Small Cell Lung Carcinoma, Neuroendocrine Neoplasms, Extra-pulmonary Neuroendocrine Carcinoma
Interventions: BI 764532, dose 1, BI 764532, dose 2, Ventana DLL3 RxDx assay; Drug · Device
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 16
States / cities: Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 13 more

Conditions: Cancer, Food Deprivation, Food Habits, Food Selection, Colorectal Cancer, Prostate Cancer, Lung Cancer, Breast Cancer, Gynecologic Cancer, Hematologic Cancer, Skin Cancer, Melanoma, Nutrition Poor, Nutritional Deficiency
Interventions: MyCarePulse and ASCENT PN; Behavioral
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 100 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Bone Cancer, Bone Tumor, Solid Tumor, Metastatic Cancer to the Bone, Metastatic Tumor to the Bone
Interventions: 153-Sm-DOTMP (Samarium-153-DOTMP); Drug
Lead sponsor: QSAM Therapeutics, Inc.; Industry
Eligibility: 15 Years to 75 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 4
States / cities: Chicago, Illinois • Columbia, Missouri • New Brunswick, New Jersey + 1 more

About this Lung Cancer clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Lung Cancer as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Lung Cancer.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Lung Cancer clinical trials

How Lung Cancer studies are organized in the registry

Filter and sort this condition

Live official records

Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC

A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations

ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers

Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma

The Longitudinal Impact of Respiratory Viruses on Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Cell Transplantation (The RV-BOS Study)

A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Small Cell Lung Cancer

Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents

Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer

A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors

DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers

The Florida ASCENT Study

A Dose Finding Study to Treat Bone Tumor(s)

About this Lung Cancer clinical trials directory page